Biological data for pharmacokinetic modeling and risk assessment
Read Online
Share

Biological data for pharmacokinetic modeling and risk assessment report of a workshop convened by the U.S. Environmental Protection Agency and ILSI Risk Science Institute. by

  • 972 Want to read
  • ·
  • 55 Currently reading

Published by U.S. Environmental Protection Agency in Washington, D.C .
Written in English

Subjects:

  • United States. -- Environmental Protection Agency. -- Office of Health and Environmental Assessment

Book details:

Edition Notes

ContributionsUnited States. Environmental Protection Agency. Office of Health and Environmental Assessment
The Physical Object
FormatMicroform
Pagination1 v. (various pagings)
ID Numbers
Open LibraryOL22419659M

Download Biological data for pharmacokinetic modeling and risk assessment

PDF EPUB FB2 MOBI RTF

Biological data for pharmacokinetic modeling and risk assessment: report of a workshop convened by the U.S. Environmental Protection Agency and ILSI Risk Science Institute.. [United States. Environmental Protection Agency. *The Pharmacokinetics Workgroup (PKWG) is convened by the National Center for Environment Assessment (NCEA) to support and promote consistent application of the best science in the field of mathematical modeling of pharmacokinetic processes and the data supporting it as applied in human health risk assessment. A PB-PK model that accurately describes the behavior of CCl 4 in rats was developed by using fundamental biological data and was validated by comparison with rat and human kinetic data. The model was capable of describing CCl 4 pharmacokinetics .   Tissue dosimetry, physiologically-based pharmacokinetic modeling, and cancer risk assessment. Chemical risk assessment is a complex process that requires integration of various biological data from test species Cited by: 8.

Physiologically based pharmacokinetic modeling in risk assessment Development of Bayesian population methods blood flow in man by physiologically based pharmacokinetic modeling of inhalation exposure to toluene. Toxicology, (), data, and are widely used in pharmacokinetic . The mechanistic basis allows PBPK models to be used to determine if results from different experimental designs are consistent, and to explore possible mechanisms responsible for unexpected or unusual data. PBPK modeling has been used to great effect for interspecies extrapolation, both among animal models Cited by: 5. Extensive use of rapidly developing in vitro and structure-ac- tivity relationship techniques is needed to provide the data required for the large number of hazardous chemicals currently contaminating the environment. Keywords: Pharmacokinetics; PBPK modeling; Risk assessment Cited by: excretion (ADME) data in agricultural chemical safety assessments. Crit Rev Toxicol. Jan;36(1) Clewell HJ 3rd, Andersen ME, Barton HA. A consistent approach for the application of pharmacokinetic modeling in cancer and noncancer risk assessment.

The BE approach integrates available pharmacokinetic data necessary to convert, in a biological medium, a current exposure guidance value into an equivalent concentration. A range of pharmacokinetic data and approaches not limited to PBPK modeling Cited by: Environmental Protection Agency (EPA) (b) Update to the health assessment document and addendum for dich- loromethane (mhyle chloride): pharmacokinetics, mechanism of action, and epidemiology. External Review Draft, EPA///A. Environmental Protection Agency (EPA) () Biological data for pharmacokinetic modeling and risk by: Office of Health and Environmental Assessment. Title(s): Biological data for pharmacokinetic modeling and risk assessment: report of a workshop convened by the U.S. Environmental Protection Agency and ILSI Risk Science . Physiologically-based pharmacokinetic (PBPK) modeling offers a scientifically-sound framework for integrating mechanistic data on absorption, distribution, metabolism and elimination to predict the time Cited by: